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Abstract
Introduction: Gestational diabetes mellitus (GDM) is a heterogeneous disease. We hypothesized that fasting hyperglycaemia, defined as
impaired fasting glycaemia (IFG), is a marker of metabolic heterogeneity of GDM. The aim of this study was to compare selected metabolic
parameters in two groups of women with GDM, one with normal fasting glycaemia (NFG GDM) and another with IFG, to test this
hypothesis.
Material and methods: Metabolic parameters of 1025 women with GDM (mean age 29 years): glucose and insulin at 0 OGTT, glucose at
2-h oral glucose tolerance test (OGTT), body mass index before pregnancy, parity, and gestational age at diagnosis of GDM were analyzed.
Insulin resistance and b-cell function were evaluated by HOMA indexes (HOMA-IR and HOMA-B) at the diagnosis of GDM.
Results: The IFG GDM group (23%) consisted of isolated IFG (30%), IFG/IGT (60%), and IFG/DM (10%). The NFG GDM group (77%)
consisted of isolated IGT (98%) and NFG/DM (2%). Women with IFG GDM were characterized by higher prepregnancy BMI, earlier
diagnosis of GDM, higher HOMA-IR (p < 0.03), and lower HOMA-B (p < 0.01) compared to NFG GDM. In the IFGGDM group, DM was
characterized by lower HOMA-B compared with isolated IFG and IFG/IGT. In the NFG GDM group, isolated IGT and DM were characte-
rized by similar HOMA-IR and HOMA-B.
Conclusions: Impaired fasting glucose distinguishes more severe metabolic phenotypes of GDM compared toGDM with normal fasting
glucose concentrations. (Pol J Endocrinol 2009; 60 (5): 348–352)
Key words: gestational diabetes mellitus, gestational diabetes mellituss — pathophysiology, impaired fasting glycaemia, insulin resistance, b-cell
function, HOMA
Streszczenie
Wstęp: Cukrzyca ciężarnych (GDM, gestational diabetes mellitus) jest chorobą heterogenną. Autorzy przyjęli hipotezę, że hiperglikemia na
czczo spełniająca kryterium nieprawidłowej glikemii (IFG, impaired fasting glycaemia) może być znacznikiem heterogenności GDM. Celem
pracy było porównanie wybranych parametrów metabolicznych w dwóch grupach kobiet z GDM, jednej z prawidłową glikemią na czczo
(NFG, normal fasting glycaemia) i drugiej z IFG dla sprawdzenia powyższej hipotezy.
Materiał i metody: Porównano parametry metaboliczne 1025 kobiet z GDM (śr.wiek 29 lat): stężenie glukozy i insuliny na czczo, stężenie
glukozy w 2-godzinnym doustnym teście tolerancji glukozy (OGTT, oral glucose tolerance test), wskaźnik masy ciała (BMI, body mass index)
przed ciążą, ilość przebytych ciąż oraz tydzień rozpoznania GDM. Insulinooporność oraz czynność komórek b trzustki oceniono metodą
HOMA (HOMA-IR i HOMA-B) przy rozpoznaniu GDM.
Wyniki: Grupa IFG GDM (23%) składała się z podgrup z izolowaną IFG (30%), IFG/IGT (60%) oraz IFG/DM (10%). Grupa NFG GDM
(77%) skladała się z podgrup z izolowaną IGT (98%) oraz z NFG/DM (2%). Grupa IFG GDM charakteryzowała się wyższym BMI przed
ciążą, wcześniejszym rozpoznaniem GDM, większym wskaźnikiem HOMA-IR (p < 0,03) oraz mniejszym wskaźnikiem HOMA-B
(p < 0,01) w porównaniu z grupą NFG GDM. W grupie IFG GDM podgrupa z DM charakteryzowała się mniejszym wskaznikiem HOMA-B
w porównaniu z izolowaną IFG oraz IFG/IGT. W grupie NFG GDM w podgrupach z izolowaną IGT oraz IGT/DM wskaźniki HOMA-IR
oraz HOMA-B nie różniły się istotnie.
Wnioski: Występowanie nieprawidłowej glikemii na czczo u kobiet z GDM wyróżnia niekorzystny metabolicznie fenotyp w porównaniu
z kobietami z prawidłową glikemią na czczo. (Endokrynol Pol 2009; 60 (5): 348–352)
Słowa kluczowe: cukrzyca cieżarnych, cukrzyca ciężarnych — patofizjologia, nieprawidłowa glikemia na czczo, insulinooporność, czynność
komórek b, HOMA
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Introduction
Gestational diabetes mellitus (GDM) is defined as any
degree of glucose intolerance with onset or first reco-
gnition during pregnancy. Several studies [1–5] suggest
pathophysiological heterogeneity of different catego-
ries of carbohydrate metabolism disturbances, which are
classified as GDM. Recently Di Cianni et al. [6] repor-
ted that a worsening of glucose tolerance in pregnant
women was accompanied by the progression of insulin
secretory dysfunction and insulin resistance. Metabolic
characteristics of impaired fasting glucose (IFG), either
as an isolated category, combined with IGT(IFG/IGT),
or with DM(IFG/DM) in women with GDM, has not
been studied. In non-pregnant women, isolated IFG is
a consequence of insulin resistance and beta-cell dys-
function [7, 8]. The isolated IGT is due to inadequate
compensatory insulin secretion [8], the combined cate-
gory IFG/IGT is due to both types of metabolic disor-
ders [7, 8].
We hypothesized that IFG may reflect a distinct,
more severe metabolic phenotype characterized by beta-
cell dysfunction and/or insulin resistance assessed by
HOMA indexes, compared with normal fasting gluco-
se GDM.
To test this hypothesis we sought to compare selec-
ted clinical, anthropometrical, and pathophysiological
parameters in two groups of women with GDM: one
group consisted of isolated IFG combined with IGT(IFG/
/IGT) or DM(IFG/DM), and the another group consi-
sted of isolated IGT combined with DM(NFG/DM).
Material and methods
A total of 1080 GDM subjects treated at the Regional
Centre for Intensive Diabetologic and Obstetric Care at
the Dr J Biziel University Hospital in Bydgoszcz betwe-
en 2002 and 2006 were examined for the study. The dia-
gnosis of GDM was established in accordance with the
model used in Poland [9]. Modified World Health Orga-
nisation diagnostic criteria for GDM were used [9]. We
enrolled only those GDM subjects who had either normal
(60 to < 100 mg/dL) or elevated (100 to < 126 mg/dL)
fasting plasma glucose, e.g. impaired fasting glucose
according to modified WHO criteria. The data of sub-
jects who had fasting plasma glucose concentrations
≥ 126 mg/dL were eliminated for the purpose of the
present study. The following data were collected for all
women: age, prepregnancy BMI, parity, gestational age
at GDM diagnosis, insulin at 0 OGTT, and glucose at
0 and 2-h OGTT at the GDM diagnosis.
BMI was estimated by dividing the body weight (in
kilograms) by the square of the height (in metres). In-
sulin resistance and beta-cell function were assessed
using the Homeostasis Model Assessment (HOMA)
method. A HOMA value for each subject was calcula-
ted from the fasting concentrations of insulin and glu-
cose according to the equations described by Mathews
and Hosker [10] : HOMA-IR = insulin (uU/mL) × glu-
cose (mmol/L)/22.5.
HOMA-B%= (20 × insulin (uU/mL)/
/glucose (mmol/L)–3.5)
Blood samples for insulin and glucose measurements
were drawn from subjects in a fasting state. Serum glu-
cose was determined in the venous blood by the gluco-
se oxidase method on an Olympus AU 400 analyzer (re-
ference values 3.31–5.51 mmol/L) and the serum insu-
lin   concentration in the venous blood using the im-
munoenzymatic method (MEIA) on an AxSYM analyzer
(reference values 2–25 uU/mL).
Statistical analysis
Data were analyzed using Statistica software for Win-
dows by StatSoft. The Shapiro-Wilk test was used to
determine whether each variable had a normal distri-
bution. These variables were expressed as means ± SD.
The Kruskal-Wallis test and the U Mann-Whitney test
were used to compare selected groups. A value < 0.05
was defined as significant.
Results
A total of 1025 women with GDM were divided into
two main groups based on the fasting plasma glucose
concentration according to the WHO modified criteria
used in Poland: one group (n = 789–77%) of subjects
with normal fasting glucose (60 £ 100 mg/dL) — the
normal fasting glucose GDM (NFG GDM) group, and
a second group (n = 236–23%) with impaired fasting
glucose (100 £ 126 mg/dL) — the impaired fasting glu-
cose GDM (IFG GDM) group.
Compared with NFG GDM, the IFG GDM group
was characterized by a higher prepregnancy BMI,
higher HOMA-IR, and a lower HOMA-B (p < 0.01)
(Table I). The GDM was diagnosed earlier in the IFG
GDM group compared to the NFG GDM group (Table I).
The IFGGDM group was further divided into three
subgroups based on 2-hour plasma glucose concentration
during the standard 75-g OGTT according to modified
WHO criteria: isolated IFG (2-h glucose < 140 mg/dL),
IFG/IGT (2-h glucose between 140 and 200 mg/dL), and
IFG/DM (2-h glucose ≥ 200 mg/dL). Data were compa-
red to each other, isolated IFG, IFG/IGT, and IFG/DM.
Both indexes, HOMA-IR and the HOMA-B, were sligh-
tly (non-significantly) higher in IFG IGT compared with
isolated IFG.
The IFG/DM subgroup characterized significantly
lower HOMA-B compared with the other subgroups
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(p < 0.001). In the above selected subgroups of carbo-
hydrate metabolism disturbances, fasting glucose con-
centrations increased progressively in successive gro-
ups. Table II presents the results of the comparison of
parameters in the above-named subgroups.
The NFG GDM group was further divided into two
subgroups depending on 2-h glucose in 75-g OGTT test
according to WHO modified criteria [9].Women with
isolated IGT and with DM(NFG/ DM) were placed into
one category. In the NFGGDM subpopulation, 775
women (98%) had isolated IGT, and 141 women (2%)
had DM (NFG DM). The isolated IGT characterized hi-
gher BMI compared to NFG/DM. The categories did not
differ from one another in HOMA-IR and HOMA-B.
There was a trend towards a higher (non-significantly)
value of HOMA-B in the NFG DM compared to isola-
ted IGT. Table III presents the division into groups,
along with their metabolic parameters.
Table I. Metabolic parameters in the two groups of women with GDM with normal (NFGGDM) and impaired (IFG GDM)
fasting glycaemia
Tabela I. Parametry metaboliczne w dwóch grupach GDM z prawidłową (NFG GDM) i nieprawidłową (IFG GDM) glikemią
na czczo
Parameter NFG GDM IFG GDM p
N = 789 N = 236
M Me SD M Me SD
Age (years) 29.62 29.00 5.03 29.87 30.00 5.07 0.5005
Parity 1.96 2.00 1.18 2.08 2.00 1.18 0.1626
Pregnancy index at diagnose 28.73 29.00 4.28 26.73 28.00 6.45 < 0.0001
BMI [kg/m2] 22.99 21.21 4.06 25.81 24.09 6.01 < 0.0001
Insulin [mU/L] 13.30 10.70 12.16 14.80 12.70 9.43 0.1565
HOMA-IR 2.65 1.98 3.10 3.25 2.71 2.28 0.0363
HOMA-B 539.29 295.36 907.34 322.45 184.42 712.91 0.0122
Glucose at 0 OGTT [mg/dL] 84.06 85.00 8.60 108.77 106.00 9.79 < 0.0001
Glucose at 2-h OGTT [mg/dL] 155.99 152.00 18.82 155.55 152.00 34.50 0.7985
BMI — body mass index; OGTT — oral glucose tolerance test
Table II. Metabolic parameters in three subgroups of IFG GDM women according to glycaemia at 2-h OGTT
Tabela II. Parametry metaboliczne w trzech podgrupach kobiet IFG GDM w zależności od glikemii w 2-godzinnym OGTT
Parameter IFG/NGT IFG/IGT IFG/DM p
N = 70 N = 141 N = 25
M Me SD M Me SD M Me SD
Age (years) 28.73 28.00 4.46 30.06 30.00 4.93 32.04 31.00 6.67 0.0802
Parity 1.94 2.00 0.96 2.10 2.00 1.20 2.40 2.00 1.55 0.7061
Diagnosis of GDM (week) 25.81 27.50 7.20 27.09 28.00 6.21 27.20 28.00 5.41 0.7980
BMI [kg/m2] 25.67 23.34 6.86 25.57 24.09 5.49 27.58 28.03 6.34 0.3094
Insulin [mU/mL] 13.74 12.55 6.64 15.38 12.75 10.74 13.98 13.00 6.68 0.9767
HOMA-IR 2.93 2.64 1.65 3.35 2.69 2.56 3.48 3.49 1.43 0.5235
HOMA-B 257.70 228.99 156.22 366.12 182.48 859.56 135.22 97.56 127.19 0.00601–3
0.00672–3
Glucose at 0  OGTT [mg/dL] 106.41 104.5 9.08 108.63 106.00 8.81 116.50 112.50 13.34 0.01871–2
0.00021–3
0.00392–3
Glucose at 2-h OGTT [mg/dL] 117.64 120.00 15.41 162.95 160.00 18.78 218.72 214.00 19.34 < 0.00011–2
< 0.00011–3
< 0.00012–3
1IFG/NGT; 2IFG/IGT; 3IFG/DM; GDM — gestational diabetes mellitus; BMI — body mass index; OGTT — oral glucose tolerance test
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Discussion
In the whole population of GDM women in the region
of Kuyavia and Pomerania in Poland, women with nor-
mal fasting glucose (NFG GDM) were the decisive ma-
jority (77%). In the remaining percentage (23%) of wo-
men, impaired fasting glucose (IFG) occurred as an iso-
lated category and as a combined category with
IGT(IFG/IGT) or with DM(IFG/DM) according to 2-h
post-challenge glucose concentrations (IFG GDM gro-
up). These two groups of women with GDM presented
different metabolic phenotypes.
In comparison with NFG GDM, IFG GDM women
were characterized by a higher prepregnancy body
mass index (BMI), higher insulin resistance (HOMA-R),
and lower beta-cell function (HOMA-B) at the diagno-
sis of GDM.
In the latter group, GDM was diagnosed earlier than
in the NFG GDM group.
It seems that the earlier occurrence of abnormalities
of carbohydrate metabolism in the IFG GDM group
could be the result of higher insulin resistance and lo-
wer beta-cell function compared with NFG GDM, ra-
ther than the progression of NFG GDM. In the IFG GDM
group, the most frequent abnormality of glucose regu-
lation was IFG/IGT (60%); less frequent was isolated IFG
(30%); and the least frequent was IFG/DM (10%).
The results of many studies have shown a similarity
of pathophysiological mechanisms in GDM and type 2
diabetes [11–15]. In the non-pregnant population, iso-
lated IFG is due to reduced [7] or progressive decline
hepatic insulin sensitivity [8] combined with impair-
ments in basal insulin secretion and first-phase insulin
release [7, 8]. The IFG/IGT is additionally characterized
by a progressive decline of insulin secretion secondary
to the low insulin sensitivity [8].
The results of the current study suggest beta-cell
dysfunction rather than insulin resistance as the main
cause of worsening glucose tolerance status in both gro-
ups of women with GDM, irrespective of fasting gluco-
se concentrations. The more pronounced defect of in-
sulin secretion assessed by HOMA-B in the IFG GDM
group compared to the NFG GDM group is in agre-
ement with the above-cited observations in non-pre-
gnant women [7, 8].
Our results show that the IFG/IGT subgroup of wo-
men with GDM is also characterized by a slightly (non-
significantly) higher insulin secretion compared to iso-
lated IFG, and that the lowest insulin secretion is cha-
racterized by the DM(IFG/DM) subgroup compared to
isolated IFG and IFG/IGT.
The isolated IGT and NFG/DM is characterized by
a similar HOMA index value of insulin resistance and in-
sulin secretion.  A similar finding was shown by Festa et
al. [16] in non-pregnant women. These authors observed
slightly increased insulin secretion assessed by HOMA-B
in isolated IGT and DM(NFG/DM), and decreased HOMA-
B when DM was diagnosed according to fasting glucose
or both fasting and post-challenge glucose criteria.
An interesting finding in our study is the higher insu-
lin secretion in the IFG/IGT subgroup of women with GDM
compared to isolated IFG. A recently published study
shows similar findings referring to the first phase of insu-
lin secretion in the non-pregnant population [8 ].Therefo-
re, it can be suggested that IFG/IGT is a specific category
of glucose dysregulation, both in the non-pregnant po-
pulation and in women with GDM. Currently, IFG/IGT is
classified together with isolated IGT in one group.
Table III. Metabolic parameters of NFG GDM women in two subgroups according to 2-h OGTT glycaemia
Tabela III. Parametry metaboliczne w dwóch podgrupach kobiet z NFG GDM w zależności od glikemii w 2-godzinnym OGTT
Parameter NFG/IGT NFG/DM p
N=775 N=14
M Me SD M Me SD
Age (years) 29.62 29.00 5.02 29.79 30.50 5.47 0.7782
Parity 1.95 2.00 1.16 2.38 2.00 2.26 0.9234
Diagnosis of GDM (week) 28.73 29.00 4.29 28.64 29.00 3.97 0.8913
BMI [kg/m2] 23.04 22.23 4.06 20.39 19.48 3.14 0.0065
Insulin [mU/L] 13.32 10.70 12.19 11.67 7.50 8.73 0.5716
HOMA-IR 2.65 1.98 3.11 2.36 2.00 1.54 0.9841
HOMA-B 538.89 295.36 910.32 580.59 381.03 585.41 0.7139
Glucose at 0 OGTT [mg/dL] 84.07 85.00 8.61 83.21 83.50 8.40 0.7417
Glucose at 2-h OGTT [mg/dL] 154.92 151.00 17.05 215.29 206.50 18.25 < 0.0001
GDM — gestational diabetes mellitus; BMI — body mass index; OGTT — oral glucose tolerance test
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The results of the present study and  studies of other
authors [7, 8, 16] suggest similar trends in the patho-
physiology of isolated IFG, IFG/IG, isolated IGT, and
IGT/DM assessed by HOMA-IR and HOMA-B.
There are several studies on the issues of the meta-
bolic phenotype of carbohydrate metabolism disturban-
ces in pregnant women [1, 3–5]. The observations of
Ryan et al. [5] concerning the metabolic characteristics
of GDM women with fasting hyperglycaemia show
a higher insulin resistance in comparison with pregnant
women without carbohydrate metabolism disturban-
ces examined in late pregnancy. Kjos et al. [1] reported
higher prepregnancy BMI in the population of women
with GDM and with fasting hyperglycaemia in compa-
rison with GDM women with normal fasting glucose.
The mechanisms of fasting hyperglycaemia in GDM
and their relation to obesity are similar to those in type 2
diabetes [12]. They involve a combination of insulin re-
sistance, a decrease in suppression of liver glucose
production [12], and a decrease in insulin secretion for
the level to insulin resistance [17, 18].
Previous studies [3, 4, 13] report the progressive in-
crease of insulin resistance as the main cause of worse-
ning glucose tolerance from NGT through IGT to DM.
The inconformity of the results of our current stu-
dies with the above-cited studies could be partly expla-
ined by the specificity of the HOMA method, which is
based on fasting insulin and glucose, and in fact evalu-
ates basal insulin resistance and basal insulin secretion
[19, 20].
Overall, our results demonstrate the dominant oc-
currence of GDM with normal fasting glucose and the
much less frequent occurrence of GDM with impaired
fasting glucose. The latter form of GDM represents
a more severe metabolic phenotype of women with
GDM. This study suggests that the two groups of wo-
men with GDM may have different aetiological and pa-
thophysiological origins, which in turn may have im-
plications for the treatment of GDM.
It seems that women with GDM and impaired fa-
sting glucose require more frequent control of carbo-
hydrate metabolism post partum, especially those with
IFG/DM.
Conclusions
1. Isolated IFG, IFG/IGT, and IFG/DM, as a group of
women with GDM, is characterized by earlier dia-
gnosis of GDM, higher prepregnancy BMI, higher
insulin resistance, and lower beta-cell function com-
pared to GDM with normal fasting glucose.
2. The GDM with impaired fasting glucose consists of
three subgroups: isolated IFG, IFG/IGT, and IFG/
/DM, with slightly higher beta-cell function in IFG/
/IGT compared to isolated IFG, and lower beta-cell
function in DM compared to other subgroups.
3. The GDM with normal fasting glucose consists of
two subgroups: NFG/IGT and NFG/DM, with simi-
lar beta-cell function and similar insulin resistance.
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